La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
AC Immune Résultats passés
Passé contrôle des critères 0/6
AC Immune's earnings have been declining at an average annual rate of -27.7%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 65.7% per year.
Informations clés
-27.7%
Taux de croissance des bénéfices
-25.0%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | 17.0% |
Taux de croissance des recettes | -65.7% |
Rendement des fonds propres | -49.0% |
Marge nette | -390.7% |
Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Jul 26AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business
Jun 15Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being
Jun 15AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up
May 24AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Apr 05We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Mar 15Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth
Oct 06We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Jun 03Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?
Nov 25AC Immune Non-GAAP EPS of -$0.23 in-line
Jul 28Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation
Jul 06AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans
Feb 03AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates
Jun 02Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?
May 09AC Immune reports Q1 results; outlook
Apr 28How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?
Feb 28Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts
Jan 24We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely
Jan 19If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%
Dec 15Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues
Nov 19AC Immune EPS misses by CHF0.02, beats on revenue
Nov 13AC Immune and Wuxi Biologics boost development of TDP-43 antibodies
Nov 09AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 30Ventilation des recettes et des dépenses
Comment AC Immune gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 15 | -61 | 17 | 0 |
31 Mar 24 | 15 | -55 | 16 | 0 |
31 Dec 23 | 15 | -54 | 15 | 0 |
30 Sep 23 | 0 | -68 | 15 | 0 |
30 Jun 23 | 4 | -67 | 15 | 0 |
31 Mar 23 | 4 | -69 | 16 | 0 |
31 Dec 22 | 4 | -71 | 16 | 0 |
30 Sep 22 | 4 | -73 | 14 | 0 |
30 Jun 22 | 0 | -76 | 16 | 0 |
31 Mar 22 | 0 | -75 | 17 | 0 |
31 Dec 21 | 0 | -73 | 18 | 0 |
30 Sep 21 | 1 | -71 | 19 | 0 |
30 Jun 21 | 2 | -74 | 19 | 0 |
31 Mar 21 | 3 | -71 | 18 | 0 |
31 Dec 20 | 15 | -62 | 19 | 0 |
30 Sep 20 | 15 | -62 | 19 | 0 |
30 Jun 20 | 47 | -25 | 18 | 0 |
31 Mar 20 | 48 | -26 | 17 | 0 |
31 Dec 19 | 110 | 45 | 16 | 0 |
30 Sep 19 | 111 | 50 | 15 | 0 |
30 Jun 19 | 80 | 18 | 14 | 0 |
31 Mar 19 | 81 | 24 | 13 | 0 |
31 Dec 18 | 7 | -51 | 12 | 0 |
30 Sep 18 | 22 | -32 | 12 | 0 |
30 Jun 18 | 21 | -27 | 11 | 0 |
31 Mar 18 | 20 | -29 | 10 | 0 |
31 Dec 17 | 20 | -26 | 10 | 0 |
30 Sep 17 | 5 | -35 | 10 | 0 |
30 Jun 17 | 6 | -36 | 10 | 0 |
31 Mar 17 | 25 | -10 | 9 | 0 |
31 Dec 16 | 23 | -7 | 8 | 0 |
30 Sep 16 | 22 | -8 | 5 | 0 |
30 Jun 16 | 45 | 21 | 4 | 0 |
31 Mar 16 | 39 | 17 | 4 | 0 |
31 Dec 15 | 39 | 20 | 3 | 0 |
30 Sep 15 | 65 | 46 | 4 | 0 |
30 Jun 15 | 41 | 21 | 4 | 0 |
31 Mar 15 | 28 | 10 | 3 | 0 |
31 Dec 14 | 30 | 11 | 3 | 0 |
31 Dec 13 | 9 | -11 | 3 | 0 |
Des revenus de qualité: ACIU is currently unprofitable.
Augmentation de la marge bénéficiaire: ACIU is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: ACIU is unprofitable, and losses have increased over the past 5 years at a rate of 27.7% per year.
Accélération de la croissance: Unable to compare ACIU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: ACIU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Rendement des fonds propres
ROE élevé: ACIU has a negative Return on Equity (-49.02%), as it is currently unprofitable.